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Epigenetic misregulation is consistent with various non-Mendelian features of schizophrenia and bipolar disorder. To date, however, few
studies have investigated the role of DNA methylation in major psychosis, and none have taken a genome-wide epigenomic approach.
In this study we used CpG-island microarrays to identify DNA-methylation changes in the frontal cortex and germline associated with
schizophrenia and bipolar disorder. In the frontal cortex we ﬁnd evidence for psychosis-associated DNA-methylation differences in
numerous loci, including several involved in glutamatergic and GABAergic neurotransmission, brain development, and other processes
functionally linked to disease etiology. DNA-methylation changes in a signiﬁcant proportion of these loci correspond to reported
changes of steady-statemRNA level associatedwith psychosis. Gene-ontology analysis highlighted epigenetic disruption to loci involved
in mitochondrial function, brain development, and stress response. Methylome network analysis uncovered decreased epigenetic
modularity in both the brain and the germline of affected individuals, suggesting that systemic epigenetic dysfunctionmay be associated
withmajor psychosis.We also report evidence for a strong correlation betweenDNAmethylation in theMEK1 gene promoter region and
lifetime antipsychotic use in schizophrenia patients. Finally, we observe that frontal-cortex DNA methylation in the BDNF gene is
correlated with genotype at a nearby nonsynonymous SNP that has been previously associated with major psychosis. Our data are
consistent with the epigenetic theory of major psychosis and suggest that DNA-methylation changes are important to the etiology of
schizophrenia and bipolar disorder.Introduction
Schizophrenia (SZ) [MIM181500] and bipolar disorder (BD)
[MIM 125480] are etiologically related psychiatric condi-
tions,1 together termed ‘‘major psychosis.’’ Studies of major
psychosis have focused primarily on the interplay between
genetic and environmental risk factors. Twin and adoption
studies highlight a clear inherited component to both disor-
ders,2 but whereas replicated ﬁndings exist for a number of
genes, association studies are characterized by nonreplica-
tion, small effect sizes, and signiﬁcant heterogeneity.3
Several epidemiological, clinical, and molecular peculiari-
ties associated with major psychosis are difﬁcult to explain
with traditional gene- and environment-based approaches.
Such peculiarities include the noncomplete concordance
between monozygotic twins for both SZ (41%–65%) and
BD (~60%),2,4 which cannot be accounted for by only envi-
ronmental factors.3,5Other complexities ofmajor psychosis
include a ﬂuctuating disease course with periods of remis-
sion and relapse, sexual dimorphism, peaks of susceptibility
todisease coincidingwithmajorhormonal rearrangements,
andparent-of-origin effects.3 These observationshave led to
speculation about the importance of epigenetic factors in
mediating susceptibility to both SZ and BD.3
Epigenetics refers to the heritable, but reversible, regula-
tion of various genetic functions, including gene expres-sion, mediated through modiﬁcations of DNA and his-
tones.6 Epigenetic processes are essential for normal
cellular development and differentiation, and they allow
the regulation of gene function through nonmutagenic
mechanisms. The impact of DNA methylation on gene
activity has been explained by two proven mechanisms.
The ‘‘critical site’’ model puts an emphasis on the methyl-
ation of speciﬁc cytosines in transcription-factor binding
sites, responsible for reducing binding afﬁnity and thus
the transcription of mRNA.7 The ‘‘methylation density’’
model suggests that the proportion of methylated cyto-
sines across a region, rather than at any speciﬁc position,
controls chromatin conformation and thus the transcrip-
tional potential of the gene.7
The epigenetic model of major psychosis is based upon
three general principles.3 First, like the DNA sequence,
the epigenetic proﬁle of somatic cells is mitotically
inherited, but unlike the DNA sequence, epigenetic signals
are dynamic. The epigenetic status of the genome is tissue-
speciﬁc, developmentally regulated, and inﬂuenced by
both stochastic and environmental factors. Second,
because epigenetic processes regulate various genetic and
genomic functions, epigenetic factors can have profound
phenotypic effects. Genes, even those containing no
mutations or disease-predisposing polymorphisms, can
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Table 1. Demographic Data Associated with Frontal-Cortex Brain-Tissue Samples Utilized in this Study
CTRL SZ BD
Number of Tissue Samples 35 35 35
Number Hybridized 28 35 32
Mean Age and Range 44.1 (31-59) 42.6 (19-59) 45.3 (19-64)
Race 35 white 35 White 33 White 1 Black 1 Native American
Sex 26M, 9F 26M, 9F 17M, 18F
Diagnosis no axis I 27 undifferentiated 7 paranoid 1
disorganized
26 BP I 4 BP II 4 BP NOS 1 BP-SA
Psychotic Features 0 35þ 20þ, 11-, 4 unclear
Cause of Death 32 cardiac 3 other medical 14 cardiac 13 other medical 1
accident 7 suicide
12 cardiac 4 other medical
4 accidents 15 suicide
Postmortem Interval Male: 26.9 (11.7) Female: 35.50 (9.6) Male: 31.4 (17.0) Female: 30.88 (9.1) Male: 37.8 (20.6) Female: 39.59 (17.7)
Refrigerator Interval Male: 2.9 (1.6) Female: 2.83 (0.4) Male: 5.67 (4.3)* Female: 6.25 (4.1) Male: 7.80 (7.4)* Female: 13.18 (12.7)*
Brain pH Male: 6.65 (0.26) Female: 6.45 (0.30) Male: 6.44 (0.25)* Female: 6.61 (0.17) Male: 6.46 (0.26)* Female: 6.44 (0.29)
Brain Weight Male: 1486.4 (137.9)
Female: 1314.2 (106.3)
Male: 1444.6 (104.8)
Female: 1418.1 (128.8)
Male: 1467.6 (112.9)
Female: 1316.2 (111.4)
Lifetime Alcohol Use Male: 0.73 (0.94) Female: 1.00 (1.55) Male: 2.36 (2.00)** Female: 1.38 (2.00) Male: 2.86 (1.70)** Female: 2.29 (1.86)*
Lifetime Drug Use Male: 0.27 (0.70) Female: 0.17 (0.41) Male: 2.08 (2.00)** Female: 0.29 (0.76) Male: 2.93 (2.05)** Female: 1.76 (1.8)*
Summary of demographic data for the brain samples obtained from the Stanley Foundation. Comparison of brain samples utilized for microarray-based
epigenomic profiling. Given are the mean for each group (with SD). Affected individuals were found to have significantly lower brain pH (male SZ,
male BD) and higher lifetime alcohol and drug use (male SZ, male BD, female BD) compared to unaffected controls of the same sex, reflecting data reported
elsewhere. None of these demographic variables was correlated with DNA methylation.
*denotes a t test of p < 0.05 comparing affected group with controls.
**denotes a t test of p < 0.001 comparing affected group with controls.at the correct time of the cell cycle, or in the correct
compartment of the nucleus. Third, some epigenetic
signals, rather than being reset and erased during gameto-
genesis, could be transmitted meiotically across genera-
tions.8 This has obvious ramiﬁcations for the identiﬁcation
of the molecular substrate of inherited predisposition, in
which heritable phenotypic variation is assumed to result
exclusively from DNA-sequence variants.
To date, few studies have investigated the role of epige-
netic factors in major psychosis, and none has taken a
genome-wide epigenomic approach. DNA-methylation
differences have been reported in the vicinity of both cat-
echol-O-methyltransferase (COMT)9 and reelin (RELN),10
although these ﬁndings were not conﬁrmed using fully
quantitative methylation-proﬁling methods.11,12 In this
article we report ﬁndings from a comprehensive epige-
nomic study of major psychosis. Using DNA from the fron-
tal cortex—a region previously implicated in the etiology
of major psychosis13—derived from individuals with SZ,
BD, and from matched controls (CTRL), we examined
DNA methylation by utilizing two complementary
approaches. First, we performed a microarray-based epige-
nomic scan of major psychosis using CpG-island microar-
rays after enrichment of the unmethylated fraction of
brain DNA. Second, we performed a hypothesis-driven
analysis of DNA methylation across candidate genes for
which a priori evidence for a role in the etiology of major
psychosis exists. In addition, to investigate whether epige-
netic differences could be observed in the germline, we
also used CpG-island microarrays to proﬁle germline
DNA methylation in BD patients and controls. Consistent
with the epigenetic theory of major psychosis, we ﬁndTheconsiderable evidence for epigenetic changes associated
with schizophrenia and bipolar disorder.
Material and Methods
Samples
Frontal-cortex postmortem brain tissue from individuals with
DSM-IV diagnosed SZ (n¼ 35), BD (n¼ 35), andmatched controls
(n ¼ 35) was provided by the Stanley Medical Research Institute
brain-array collection (courtesy of Drs. Michael B. Knable, E. Fuller
Torrey, Maree J. Webster, and Robert H. Yolken). The samples
consisted of frozen tissue sections, which were stored at 80C
prior to DNA extraction. Demographic data associated with these
samples are summarized in Table 1. In addition, germline-DNA
samples were obtained from mature spermatozoa of BD patients
(n ¼ 20) and unaffected controls (n ¼ 20) from an ongoing study
at the Centre for Addiction and Mental Health (Toronto, Canada).
These individuals were matched for age (BD mean age ¼ 44.2;
CTRL mean age ¼ 41.3) and ethnic background (all individuals
of European ancestry). Extraction of all DNA was performed
with a standard phenol-chloroform extraction method. The qual-
ity and quantity of DNA was assessed by spectrophotometry and
agarose-gel analysis, and DNA was subsequently stored at 20C
until further use. Samples for which good-quality, nondegraded
DNA was not available were excluded from subsequent analyses.
The project has been fully approved by the Ethics Committee of
the Centre for Addiction and Mental Health, Toronto.
Enrichment of Unmethylated DNA
and Microarray Hybridization
We used our developed technology for enrichment of the
unmethylated DNA fraction and for epigenetic proﬁling with
microarrays, described in detail elsewhere.14 In brief, theAmerican Journal of Human Genetics 82, 696–711, March 2008 697
methylation-sensitive restriction enzyme HpaII (New England
Biolabs) was used to digest 1 mg of genomic DNA. DNA adaptors
(annealing products of two primers, U-CG1A and U-CG1B [see
Table S1]) were ligated to the cleaved DNA fragments, followed
by treatment with McrBC (New England Biolabs), which digests
DNA fragments containing two or more methylated cytosines,
thereby further enriching the unmethylated fraction. Adaptor-
PCR ampliﬁcation of the ligated products, with the use of primers
complementary to the adaptor sequence, consisted of 250 ng of li-
gated DNA, 2.5 mM MgCl2, 0.2 mM aminoallyl-dNTPs (15 mM
aminoallyl–20-deoxyuridine 50-triphosphate, 10 mM 20-deoxythy-
midine 50-triphosphate, and 25 mM each of 20-deoxycytidine
50-triphosphate, 20-deoxyguanosine 50-triphosphate, and 20-deox-
yadenosine 50-triphosphate), 200 pmol primer U-CG1B, and 5 U
Taq polymerase (New England Biolabs) in 1 3 PCR reaction buffer
(Sigma), to a ﬁnal volume of 100 ml. PCR conditions are adjusted in
such a way that fragments < 1.5 kb (i.e., those that are digested,
short, and thus unmethylated) will amplify preferentially. Cycling
consisted of an initial cycle at 72C for 5 min and 95C for 1 min,
25 cycles at 95C for 40 s and 68C for 2 min 30 s, and a ﬁnal
extension at 72C for 5 min. Given that the role of epigenetic
effects in disease etiology could be sex-speciﬁc and that consider-
able differences are observed in the course and prognosis of major
psychosis between males and females, we split our sample accord-
ing to gender. For the brain samples, equal amounts of amplicons
from CTRL male samples were mixed to form a male common-
reference pool, and equal amounts of amplicons from CTRL
female samples were mixed to form a female common-reference
pool. Individual samples, including all CTRL samples, were then
cohybridized with the relevant common-reference pool sample.
For the germline samples, all samples were cohybridized with
a common-reference pool made by combination of amplicons
from all CTRL samples. Samples were hybridized on 12,192
CpG-island microarrays obtained from the University Health
Network Microarray Facility in Toronto. For the brain samples,
good-quality-DNA extraction, enrichment, and microarray
hybridization was successful for 28 CTRL samples, 35 SZ samples,
and 32 BD samples. Seven of the initial 35 CTRL samples and three
of the initial 35 BD samples were excluded from the experiment
on the basis of degraded DNA that could compromise efﬁcient
enrichment of the unmethylated DNA fraction. For the germline
samples, good-quality-DNA extraction, enrichment, and microar-
ray hybridization was successful for 19 CTRL samples and 20 BD
samples. One CTRL sample was excluded on the basis of poor
DNA quantity and quality following nucleic-acid extraction.
Microarray Data Preprocessing
Initial array-image processing and quality control was performed
with GenePix Pro 6.0 (Molecular Devices). The array signals were
background-corrected with NormExp and normalized with
weighted block-by-block LOWESS normalization. Spots with
ambiguous genome locations, including spots with no sequence
or annotation, repetitive spots, and translocation hotspots were
removed, leaving a total of 7834 spots.
Normality Testing
Several analyses assumed data to be drawn from a normal distribu-
tion; hence the need for normality testing. Log-intensity ratios for
each spot were subjected to the Lilliefors test for normality. The re-
sultantpvalues for all spotswereadjusted formultiple testingbyuse
of Benjamini and Hochberg’s false-discovery rate (FDR) method.15698 The American Journal of Human Genetics 82, 696–711, MarchMicroarray-Data Analysis
For analyses comparing affected individuals to unaffected individ-
uals, affected samples were either grouped by diagnosis (i.e., SZ
versus CTRL and BD versus CTRL) or, given increasing evidence
for an etiological overlap between SZ and BD,1,16 grouped together
into a ‘‘major psychosis’’ group (i.e., psychosis versus CTRL).
Limmawas used to analyze each array spot for differential methyl-
ation between affected and unaffected samples. Each spot was
assigned a raw p value based on a moderated t statistic. To correct
for multiple testing, the set of raw p values were converted to false-
discovery rates (FDR) according to Benjamini and Hochberg.15
Gene-Ontology Analysis
A novel gene-ontological investigation approach was designed to
determine if any common functional trends are associated with
the genes exhibiting differences between groups. For each group
interrogated, only those loci exhibiting a signiﬁcance value of
less than p ¼ 0.01 from a spotwise t test were selected, in order
to include only those loci likely to have a true DNA-methylation
difference between groups. Gene IDs within 1 kb of these array
loci were obtained from the microarray annotation data and
cross-referenced with the April 2007 build of the Gene Ontology
Database to obtain gene-ontology (GO) categories associated
with each microarray locus. All loci and corresponding mean
fold change values were sorted into categories on the basis of their
GO classiﬁcations, and the distribution of each GO category was
compared with a paired t test and themore conservativeWilcoxon
Signed Rank test. In both cases, p values were adjusted with FDR to
correct for multiple testing. Data were then sorted by FDR p value,
revealing the most signiﬁcantly different GO categories.
Network Analysis of Microarray Data
In order to investigate whether DNA methylation is coordinated
across different loci, we utilized a novel network-based
approach.17 For brain samples, this analysis was performed on
twenty male SZ samples and on an equal number of male CTRL
samples—the other diagnostic groups were not included in this
analysis because of their small sample sizes. We identiﬁed the
top 700 methylation-variable spots across the samples in each
group. The union of these two sets, consisting of 1041 spots,
was chosen for network reconstruction. To ﬁnd connections
between methylation at speciﬁc genomic regions (nodes), their
methylation log intensities were modeled by a linear combination
of the methylation log intensities at the remaining spots. After
regression, the correlation between the minimized residuals was
calculated for measuring the direct association between the two
spots. Estimation of correlation and p value was accomplished
by a regularized covariance estimator that addresses the issue of
small size and a larger number of variables (20 is much smaller
than 1042).18 As a control for the network analysis, in each of
the 20 CTRLmicroarrays, we randomized the IDs of the 1041 spots
and proceeded with the same estimator. A raw p value of 107 was
then chosen to cut off the insigniﬁcant pairwise correlations. A
connection was drawn between a pair of spots whose correlation
p value survived the cut. The structure of each network was ex-
plored by calculation of the transitivity (quantiﬁcation of the con-
nectivity between a spot’s neighbors) and assortativity (quantiﬁca-
tion of the tendency of attachment between high-connection
spots). The modular structure of a network was detected by a parti-
tioning algorithm17 that maximizes the within-module connec-
tion densities at the expense of between-module connection2008
densities. The analysis was repeated on the germline BD and CTRL
samples.
Correlation with Lifetime Antipsychotic Use
Linear regression was performed on psychosis patients, with
log-intensity ratios for each spot applied as dependent variables
and lifetime dosages of antipsychotics applied as independent
variables. Base-2 logarithms of the dosages were taken for the
regression due to their wide spread. After the regression, p values
based on F-statistics were gathered for all spots and converted to
FDR to control for multiple testing.
Bisulﬁte Treatment of Genomic DNA
Bisulﬁte treatment was performed by use of a standard protocol. In
brief, ~500 ng of genomic DNA was denatured in 0.3 M NaOH for
15min at 37C. After the addition of freshly prepared 3.5M sodium
metabisulﬁte (Sigma) and 1 mM Hydroquinone (Sigma) solution,
sampleswere subjected to a5hr incubationat 55Cunder exclusion
of light. The samples were then puriﬁed with QIAGENDNA-puriﬁ-
cation columns. Recovered samples were desulfonated in 0.3 M
NaOH for 15 min at 37C and neutralized. DNA was precipitated
overnight in ethanol at 20C and resuspended in 50 ml buffer EB
(QIAGEN). Bisulﬁte-treated DNAwas stored at –80C until needed.
Bisulﬁte Primer Design and PCR Ampliﬁcation
Primers were designed with either MethPrimer (available online)
or Pyrosequencing Assay Design Software v1.0.6 (Biotage,
Uppsala, Sweden). For loci nominated from microarray analyses,
primers were designed, where possible, to span a region contain-
ing potentially informative HpaII sites in the vicinity of the signif-
icant clone on the CpG-island microarray. Where necessary, larger
regions were covered by use of several overlapping amplicons. For
selected candidate genes, the primary focus of analysis was
promoter CpG islands. In some cases (e.g., COMT and BDNF),
additional exonic regions in the vicinity of known genetic poly-
morphisms were also investigated. Where candidate genes had
been previously investigated by other groups (RELN and COMT),
we aimed to ensure that the same regions were adequately covered
by our analyses. A full list of primer sequences and annealing tem-
peratures for each PCR reaction can be found in Table S1. PCR am-
pliﬁcations were performed with a standard hot-start PCR protocol
in 25 ml volume reactions containing 3 ml of sodium-bisulﬁte-
treated DNA, 1 mM primers, and a master mix containing hot-start
Taq polymerase (Sigma). All PCR reactions were checked on a 1.0%
agarose gel to ensure successful ampliﬁcation and speciﬁcity
before proceeding with pyrosequencing or MS-SNuPe.
Site-Speciﬁc DNA-Methylation Analysis
with Pyrosequencing and MS-SNuPe
For pyrosequencing analysis, bisulﬁte-PCR products were
processed according to the manufacturer’s standard protocol
(Biotage). In brief, 4 ml of streptavidin-sepharose beads (Amersham
Biosciences, Piscataway, NJ, USA) and 40 ml of binding buffer
(10 mM Tris-HCl, 1 mM EDTA, 2 M NaCl) were mixed with 40 ml
of PCR product for 10min at room temperature. The reactionmix-
ture was placed onto a MultiScreen-HV, Clear Plate (Millipore, Bill-
erica, MA, USA). After application of the vacuum, the beads were
treated with a denaturation solution (0.2 N NaOH) for 1 min and
washed twice with washing buffer (10 mM Tris-acetate at pH 7.6).
The beads were then suspended with 24 ml of annealing buffer
(20 mM Tris-acetate, 2 mM Mg-acetate at pH 7.6) containing 8Thepmol of sequencing primer. The template-sequencing primer mix-
ture was transferred onto a PSQ 96 Plate (Biotage), heated to 90C
for 2 min followed by 60C for 10 min, and ﬁnally cooled to
room temperature. Sequencing reactions were performed with
a PSQ96 SNPReagent Kit (Biotage) according to themanufacturer’s
instructions. The percentagemethylation at each CpG site was cal-
culated from the rawdata by use of Pyro-Q-CpGSoftware (Biotage).
MS-SNuPe analysis was performed with ABI SNaPshot reagents
(Applied Biosystems) by use of a method developed in our labora-
tory. Extension products were separated on an ABI3100 Genetic
Analyzer (Applied Biosystems). Methylation data from pyrose-
quencing and MS-SNuPe analysis were analyzed by use of SPSS
v14 (Lead Technologies) with standard t tests and ANOVA.
Genotyping of COMT and BDNF SNPs
Nonsynonymous SNPs in COMT (rs4680–val108/158met) and
BDNF (rs6265–val66met) were genotyped with the pyrosequenc-
ing assays designed to interrogate the density of methylated cyto-
sines in these regions. In addition, genotypes were double-checked
by use of the ABI TaqMan Allelic discrimination method utilizing
Assay-on-Demand reagents provided by the manufacturer (Ap-
plied Biosystems) and the ABI 7900HT Sequence Detection Sys-
tem. DNA methylation at surrounding CpG sites was compared
between samples grouped by genotype with standard t tests.
Results
Overview of Experimental Strategy
This study utilized two complimentary approaches for
detection of DNA-methylation differences associated
with major psychosis. Our ﬁrst strategy involved enrich-
ment of the unmethylated fraction of genomic DNA and
subsequent hybridization on CpG-island microarrays. SZ
and BD samples were compared to unaffected CTRL
samples both separately and, given increasing evidence
for an etiological overlap between the two disorders,1,16
as a combined major-psychosis group. Of the genomic
regions showing a signiﬁcant difference between affected
and unaffected groups, a number of loci were of particular
interest given our prior knowledge about the etiology of
the disorder, and a subset of these were selected for subse-
quent bisulﬁte-based ﬁne-mapping of methylated cyto-
sines for veriﬁcation of our microarray approach. We also
employed gene-ontology analysis to uncover functional
pathways epigenetically altered in major psychosis, and
we utilized novel network-based analyses to investigate
epigenetic modularity in affected individuals and controls.
Using demographic data available from the brain samples,
we investigated correlations between DNA methylation
and variables including lifetime antipsychotic intake.
Our second major strategy involved bisulﬁte-based ﬁne-
mapping across ten candidate genes previously implicated
in major psychosis and principally nominated from ge-
netic association and expression studies of both SZ and BD.
Methylomic Proﬁling of Brain DNA
Figure 1 illustrates raw p values for microarray signal inten-
sity versus fold change observed for comparisons betweenAmerican Journal of Human Genetics 82, 696–711, March 2008 699
brain DNA from major-psychosis patients and unaffected
controls, matched for sex. Signiﬁcant (FDR < 0.05) mean
differences were found for spots associated with a number
of genes (Table S2 and Figure 2). Many of these loci are
consistent with our knowledge about the neurobiological
and genetic systems involved in major psychosis, includ-
ing several glutamatergic and GABAergic genes, loci
involved in neuronal development, and loci in regions
highlighted in genetic linkage studies (Table S3).
Although our initial analyses separated samples by sex,
we were also interested in the overlap between males and
females. DNA methylation in SZ males and SZ females
was signiﬁcantly correlated (r2 ¼ 0.13, p ¼ 8.1e-26),
suggesting that there are SZ-associated epigenetic changes
common to both sexes. Of particular interest was evidence
for FDR-signiﬁcant hypermethylation in both male and
female samples in the vicinity of two genes. The ﬁrst is
RPP21 (male SZ FDR ¼ 0.025; female SZ FDR ¼ 0.021),
which encodes a component of ribonuclease P, a protein
complex that generates mature tRNA molecules by cleav-
ing their 50-ends19. The second is KEL (male SZ FDR ¼
0.04; female SZ FDR ¼ 0.044), encoding the Kell blood-
group glycoprotein.20 Interestingly, both regions are also
FDR-signiﬁcantly hypermethylated in female BD samples
(RPP21 FDR ¼ 0.045; KEL FDR ¼ 0.045). For BD, however,
Figure 1. Frontal-Cortex DNA-Methyla-
tion Differences
Volcano plots showing raw p values for
differential DNA methylation versus fold
change observed when the hypomethy-
lated fraction of brain DNA from psychosis
patients was compared to that from unaf-
fected individuals by use of 12K CpG-island
microarrays. Each spot (red and black)
represents an array probe averaged across
all individuals in a group, with red spots
denoting probes with FDR < 5%. SZ indi-
cates schizophrenia, BD indicates bipolar
disorder, and PSY indicates combined
psychosis group (SZ and BD).
no signiﬁcant correlation was found
between males and females, suggest-
ing that sex-speciﬁc etiological factors
may play a stronger role.
Gene-expression data for the sam-
ples used in this study are available
from the Stanley Medical Research In-
stitute Online Genomics Database.21
Figure 3 illustrates two examples of
the available expression data ob-
tained from this database. Figure
3A highlights downregulation of
NR4A2, a gene found to be hyperme-
thylated in female SZ samples (FDR
¼ 0.021). For NR4A2, nine out of 24
studies on SZ samples show signiﬁcantly reduced
expression, with the overall analysis across all mRNA stud-
ies in the Stanley Array Collection being highly signiﬁcant
(p < 0.00001). Figure 3B highlights signiﬁcant downregu-
lation of GLRX5, which we found to be hypermethylated
in male SZ samples (FDR ¼ 0.04), across expression studies
on SZ brains in the Stanley Array Collection (p ¼ 0.003).
Figure 2 summarizes the available expression data for all
FDR-signiﬁcant DNA-methylation changes. Interestingly,
82% of the loci found to be hypermethylated inmajor-psy-
chosis samples for which expression data are available (40
out of 49) are signiﬁcantly downregulated in at least one
gene-expression study, with 24% (12 out of 49) showing
signiﬁcant downregulation of expression averaged across
all mRNA studies performed on these samples in either
SZ, BD, or both. The story for hypomethylated samples is
more complex, with only 34% of loci for which gene ex-
pression data are available (11 out of 32) showing signiﬁ-
cant upregulation in at least one gene-expression study.
Analysis of Demographic Data, Brain-Tissue
Parameters, and Lifetime Antipsychotic Use
No FDR-signiﬁcant correlations were found between any of
the available demographic variables (PMI, brain weight,
brain pH, lifetime alcohol use, and lifetime illicit-drug
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Figure 2. FDR-Significant DNA-Methylation Differences Associated with Major Psychosis
A positive fold change (red) corresponds to lower DNA methylation in the affected group, and a negative fold change (blue) corresponds
to higher DNA methylation in the affected group. Also shown are gene-expression data from the same group of samples obtained from the
Stanley Research Foundation database. Dark yellow/green corresponds to significant transcript up-/downregulation in a meta-analysis of
all expression studies performed on these samples, and light yellow/green corresponds to evidence of significant up-/downregulation
from at least one study. Orange indicates that expression has been reported as altered in both directions in different studies. Grey denotes
missing data.use) and DNA methylation. Methylation of a CpG island
located ~30kb upstream of the gene-encoding mitogen-
activated protein kinase kinase I (MEK1) was found to be
signiﬁcantly correlated with lifetime antipsychotic use in
male SZ samples (n ¼ 25), with higher lifetime antipsy-
chotic use associated with lower DNA methylation
(Figure 4A) (r2¼0.6, p¼6.8E-06, FDR¼0.04). Interestingly,
a similar correlation in the samedirection is alsoobserved in
female SZ samples (Figure 4B), although this does not reach
FDR signiﬁcance due to the small number (n¼ 9) of samples
with availablemedication data (r2¼ 0.5, p¼ 0.04). No such
correlation is observed in the BD samples.
Methylomic Proﬁling of Germline DNA
Figure 5 illustrates raw p values for array signal intensity
versus fold change observed in our comparison of germline
DNA from BD patients and unaffected CTRLs. No FDR-
signiﬁcant differences were observed between the two
groups. A comparison of the largest psychosis-associated
DNA-methylation differences in the germline analysisThe Awith those in the brain DNA analysis, taking loci with
a raw p < 0.001, found no overlap between datasets.
Site-Speciﬁc CpG-Methylation Analysis
in Selected Genes
After microarray analysis, we tested a number of loci to
further verify the microarray approach. From the genes
listed in Table S3, we quantitatively measured site-speciﬁc
CpG methylation upstream of DTNBP1 (n ¼ 30), GRIA2
(n ¼ 39), HCG9 (n ¼ 31), HELT (n ¼ 26), KCNJ6 (n ¼ 26),
LHX5 (n ¼ 24), MARLIN-1 (n ¼ 28), NR4A2 (n ¼ 24),
RPL39 (n ¼ 25), SLC17A7 (n ¼ 24), TMEM59 (n ¼ 30), and
WDR18 (n ¼ 29). Given that our enrichment strategy was
based on differential cleavage of HpaII sites, we focused
primarily on these and surrounding CpG positions located
in or near genomic regions corresponding to speciﬁcmicro-
array probes.
Our site-speciﬁc CpG analyses show good agreement with
data obtained from microarray analysis, although the abso-
lute differences observed are generally small. Two examplesmerican Journal of Human Genetics 82, 696–711, March 2008 701
Figure 3. Examples of Data Obtained from the Stanley Research Foundation Expression Database
Shown is down-regulation of (A) NR4A2 and (B) GLRX5 (alternative name C14orf87) in SZ samples obtained from the Stanley Array
Consortium. Data points refer to the relative expression fold change in the affected group relative to control samples. Scale bars denote
95% confidence intervals.are shown in Figure 6 for regions upstream of the genes
WDR18andRPL39.Microarrayanalysis (Figure6A)predicted
these regions to be hypomethylated in SZ male samples and
hypermethylated in BD female samples, respectively.
Figure 6B shows pyrosequencing data conﬁrming WDR18
hypomethylation in male SZ samples compared to controls
(n ¼ 29, average methylation 17% versus 25%, p < 0.001).
This region contains a putative binding site for the brain-
expressed transcription factor c-myb, known to be blocked
by CpGmethylation22(Figure 6C). Pyrosequencing also ver-
iﬁed RPL39 hypermethylation in BD female samples (n ¼
25, 28% versus 22%, p ¼ 0.009), especially at a CpG located
withinputativebindingsites for severalbrain-expressedtran-
scription factors, PAX-523 and NF-kB,24 which are known to
be affected by DNAmethylation (Figure 6C). Example pyro-grams across both regions showing representative affected
and unaffected individuals are shown in Figure 6D.
In addition to WDR18 and RPL39, we were able to con-
ﬁrm signiﬁcant DNA-methylation differences in MARLIN-1,
postulated to be hypermethylated in affected female sam-
ples from microarray analysis. Average methylation of
aHpaII site located in the genomic region spanning themi-
croarray clone and falling in a putative binding site for
a Pbx1/Meis1 heterodimer was 84% in unaffected controls
compared to 93% in SZ females (p ¼ 0.04) and 91% in the
combined major-psychosis female group (p ¼ 0.03). Inter-
estingly, whereas only 13% of unaffected control samples
were fully methylated, 71% of SZ females and 47% of the
combined female major-psychosis group were fully meth-
ylated. Other signiﬁcant DNA-methylation differencesFigure 4. DNA Methylation and Life-
time Antipsychotic Use
Correlation between DNA methylation in
the promoter of the mitogen-activated
protein kinase kinase I gene (MEK1) and
lifetime antipsychotic use in (A) male
schizophrenia samples (r2 ¼ 0.6, p ¼
6.76E-06) and (B) female schizophrenia
samples (r2 ¼ 0.5, p ¼ 0.04).
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were observed for CpG sites upstream of DTNBP1 and
HCG9, conﬁrming hypermethylation in affected female
samples relative to controls, as predicted by microarray
data for both genes (DTNBP1: 62% versus 58%, p ¼ 0.04;
HCG9: 20% versus 15%, p ¼ 0.04).
Overall signiﬁcantDNA-methylation differences were ob-
served inﬁve of the 12 speciﬁc regions tested.However, even
in the regionswherenooverall signiﬁcantCpG-methylation
differences were detected, changes were consistently in the
direction predicted by our microarray analysis. The regions
tested with bisulﬁte sequencing are somewhat arbitrary,
and it is likely that the speciﬁc critical CpG sites causing dif-
ferential enrichment (and thus microarray signal intensity)
werenot included inall theamplicons tested. Fiveconﬁrmed
loci out of 12 tested (~40%) is thus a good rate of veriﬁcation,
especially given that no DNA-methylation differences were
observed across any of the 12 arbitrarily chosen negative-
control array regions tested (ACTL6A, BCL11A, DDX1,
DUSP10, GNL1, GPR160, LGI2, REV3L, PTPNS1, PHGDHL1,
STIL, and ZNF218) or across any of the a priori psychosis-
candidate genes, which were not selected on the basis of
microarray analysis (see below). These data suggest that
a substantial proportion of epigenetic differences detected
in our microarray experiments are real and that the conclu-
sions drawn from the full array dataset are likely to be based
on genuine DNA-methylation changes.
Gene-Ontology Analysis of Brain Methylomic Data
The top 60 GO categories for each diagnostic group can be
seen in Figure 7, and Table S4 lists all signiﬁcant GO
categories with a p < 0.01. GO categories detected by this
analysis included genes involved in the epigenetic regula-
tion of transcription and development. Of particular inter-
est to the etiology of psychosis were the FDR-signiﬁcant as-
sociations for ‘‘response to stress’’ in male BD samples and
Figure 5. Germline DNA-Methylation Differences
Volcano plot showing raw p values for differential DNA methyl-
ation versus fold change observed when the hypomethylated
fraction of germline DNA from BD patients was compared to
that from unaffected individuals by use of 12K CpG-island
microarrays. No FDR-significant DNA-methylation differences
were observed.
for ‘‘brain development’’ in both female BD samples
and female SZ samples. In addition, consistent with
the postulated link between mitochondrial function
and psychosis,25 several ‘‘mitochondrial function’’ GO
categories showed signiﬁcantly different distributions
in the affected individuals compared to controls.
Modularity in DNA-Methylation Microarray Data
In the brain, the averagenumber of connections between
nodes (representing correlated methylation observed
between different genomic loci) is higher in the SZ group
compared to the CTRL group (2.7 versus 1.7) (Figure 8A).
The large clustering coefﬁcient (CTRL¼ 0.17, SZ¼ 0.22), and
its decrease with increasing connections in both sample
groups, suggests that both are hierarchically modular. The
lack of clustering in a series of simulated ‘‘random’’ datasets
suggests that this modularity is likely to be a real biological
phenomenon (Figure 8B). Assortativity is higher in SZ
(knn ¼ 9) compared to CTRL (knn ¼ 6), probably reﬂecting
the higher number of connections between nodes in SZ
(Figure 8C). Although the number of modules (CTRL ¼ 42,
SZ ¼ 43) and median size of modules (CTRL ¼ 10, SZ ¼ 11)
is approximately the same in both groups, the degree of
modularity is higher in CTRL (0.56) than in SZ (0.44),
suggesting some epigenetic dysfunction in affected individ-
uals (Figure 9). A similar pattern is seen in the germline,
with higher connectivity (3.9 versus 1.5) and assortativity
(15 versus 7) in affected individuals compared to controls,
a high degree of clustering in both groups (CTRL ¼ 0.14,
BD¼ 0.17), but highermodularity in unaffected individuals
(0.42 versus 0.33).
DNA-Methylation Analysis of Psychosis-Candidate
Genes in Brain DNA
The second approach utilized in this study assessed
DNA methylation across speciﬁc candidate-gene regions
with sodium bisulﬁte treatment and subsequent pyrose-
quencing analysis to quantitatively measure the density
of methylated cytosines. We found little evidence of any
psychosis-associated DNA-methylation differences in any
of the ten genes tested (Table S5), including the promoter
regions of COMT and RELN found to be differentially
methylated in previous studies. Nonsynonymous SNPs in
both COMT (rs4680–val108/158met) and BDNF (rs6265–
val66met) create or abolish exonic CpG sites. In COMT,
surrounding CpG sites were highly methylated (>95%)
in all samples tested, with no correlation between
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genotype and DNA methylation. In BDNF there was
modest evidence for an association between genotype
and DNA methylation. Of the samples tested, 74% were
CC (val homozygotes) and 26% were CT or TT (met
carriers). Val homozygotes had signiﬁcantly higher DNA
methylation across the exonic region proﬁled with pyrose-
Figure 6. Bisulfite Modification and
Pyrosequencing Verification of CpG-
Methylation Differences in Two Genes
Nominated from Microarray Analysis
(A) Microarray signal intensity for probes
located in CpG islands in the promoter
region of WDR18 and RPL39. Scale bars
denote 95% confidence intervals. For
WDR18, male SZ samples had significantly
higher intensities than did unaffected con-
trol samples (raw p ¼ 4.5E-05, FDR
corrected ¼ 0.05), indicating hypomethy-
lation in affected individuals. For RPL39,
female BD samples had significantly lower
intensities than unaffected control sam-
ples (raw p ¼ 4.0E-05, FDR corrected ¼
0.02), indicating hypermethylation in af-
fected individuals.
(B) Bisulfite mapping across amplicons
spanning regions interrogated by CpG-
island microarrays confirms DNA-methyla-
tion changes predicted by microarrays:
shown are WDR18 hypomethylation in
male SZ samples (p < 0.001) and RPL39
hypermethylation in female BD samples
(p ¼ 0.009).
(C) Predicted transcription-factor binding
sites in the regions of WDR18 and RPL39
analyzed by pyrosequencing. Boxes indi-
cate CpG sites with the largest DNA-meth-
ylation differences in affected individuals.
(D) Example pyrograms demonstrating
relative WDR18 hypomethylation in a SZ
male sample and RPL39 hypermethylation
in a BD female sample.
quencing (average methylation ¼
83% versus 78%, p ¼ 0.02), with
CpG1 (86% versus 77%, p ¼ 0.01)
and CpG3 (79% versus 71%, p ¼
0.03) showing the largest differences
(see Figure 10).
Discussion
In this study we performed a microar-
ray-based epigenomic scan using
CpG-island microarrays and found
psychosis-associated brain-DNA-
methylation differences in numerous
loci, including many genes that have
been functionally linked to disease etiology. Consistent
with increasing evidence for altered glutamatergic and
GABAergic neurotransmission in the pathogenesis of
major psychosis,26,27 we identiﬁed epigenetic changes in
loci associated with both of these neurotransmitter
pathways.
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Glutamate is the most abundant fast excitatory neuro-
transmitter in the mammalian nervous system, with a criti-
cal role in synaptic plasticity. Several lines of evidence link
the glutamate system topsychosis, in particular the observa-
tion that glutamate-receptor agonists can cause psychotic
symptoms in unaffected individuals. Probes associated
with two glutamate-receptor genes—one near WDR18,
located ~10 kb upstream of the NMDA-receptor-subunit
gene NR3B (also known as GRIN3B) and another in the
promoter of the AMPA-receptor-subunit gene GRIA2—were
found to be hypomethylated in SZ and major-psychosis
males. Dysregulation of both NMDA and AMPA glutamate
Figure 7. Gene-Ontology Analysis
The top 60 GO categories for each diagnostic group (SM ¼ SZ male, SF ¼ SZ female, BM ¼ BD male, BF ¼ BD female). Colors denote raw
p values. See Table S4 for additional data.
Figure 8. Network Analysis of DNA-Methylation Microarray Data
(A) The average number of connections between nodes is higher in the SZ sample group (2.7) compared to the CTRL sample group (1.7).
(B) The clustering coefficient is high in both groups (CTRL¼ 0.17, SZ¼ 0.22) and decreases with increasing connections, suggesting that
both groups are hierarchical to the same degree.
(C) Assortativity was found to be higher in SZ (knn ¼ 9) compared to CTRL (knn ¼ 6), reflecting the higher number of connections be-
tween nodes in the SZ data. A simulated dataset generated by random shuffling of microarray data produced a network with a low number
of connections and a low clustering coefficient.
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receptors is important in the etiology of major psychosis,28
andGRIA2 expression is altered in thebrainsof SZpatients.29
Various types of glutamate transporters are present in
the plasma membranes of glial cells and neurons. Our
data suggest that two vesicular glutamate transporters
(VGLUTs), which pack glutamate into synaptic vesicles,
are epigenetically altered in major psychosis. Given the
link between DNA methylation and gene transcription,
our data concur with data from gene expression studies
and the observation that VGLUT1 and VGLUT2 are
expressed in a complementary manner in cortical neu-
rons.30 VGLUT1, which was hypermethylated in SZ
female samples, is downregulated in the brains of SZ
patients.31 In addition, VGLUT2, which is upregulated in
SZ patients,32 is hypomethylated in SZ females.
Several other glutamatergic genes showed evidence of
epigenetic dysregulation in major psychosis. GLS2, which
encodes a glutaminase enzyme that catalyzes the hydroly-
sis of glutamine to glutamate, was hypermethylated in SZ
male samples. Previous studies report that glutaminase
expression is altered in the pathology of SZ.33 The gene
encoding Secretogranin II (SCG2), a secretory protein
located in neuronal vesicles that is known to stimulate
the release of glutamate, was hypomethylated in major-
psychosis females relative to unaffected controls. SCG2
expression is known to be modulated by both chronic
PCP exposure, which mimics symptoms of major psycho-
sis,34 and lithium treatment.35
Unlike glutamate, which is a strong excitatory
neurotransmitter, GABA acts as a potent inhibitory neuro-
transmitter. Hypofunctioning GABAergic interneurons
appear to be important in the etiology of major psycho-
sis.27 Our data suggest that MARLIN-1, a RNA-binding
protein that is widely expressed in the brain and regulates
the production of functional GABA(B) receptors,36 is
hypermethylated in SZ, BD, and major-psychosis female
Figure 9. Reduced Epigenetic Modularity in Major Psychosis
Partial-correlation network analysis of microarray data illustrating significant connections between nodes (p < 1e-7) demonstrating
strong hierarchical modularity for (A) male CTRL samples (n ¼ 20) and (B) male SZ samples (n ¼ 20) but not for (C) a randomly shuffled
dataset. Although modularity is apparent in both sample groups, it is lower in the SZ group (0.44) than in the CTRL group (0.56). A
similar pattern of modularity is seen in the comparison of methylation between germline male BD samples (0.33) and unaffected CTRLs
(0.47).
Figure 10. BDNF genotype and DNA Methylation
Association of BDNF genotype with DNA methylation at nearby
exonic CpG sites in DNA obtained from frontal-cortex brain
tissue.
(A) the exonic region of BDNF covered by our bisulfite mapping
indicating the four CpG sites tested.
(B) DNA methylation at the four CpG sites in the vicinity of
rs6265. Asterisk denotes t test of p < 0.05, bars denote
mean standard error.
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samples. In addition, KCNJ6, a G protein-coupled inwardly
rectifying potassium channel that has been linked to the
regulation of GABA neurotransmission,37 was found to
be hypermethylated in SZ and major-psychosis males.
Increasing evidence suggests that both the glutamate and
GABA systems are synergistically involved in major
psychosis,26 supporting our observation of increasedHELT-
promoter methylation in SZ and BD female samples. HELT
is known to determine GABAergic over glutamatergic neu-
ronal fate in the developing mesencephalon.38
We observed evidence for epigenetic dysregulation near
several genes involved in neuronal development in the
brain. WNT1, an integral part of the Wnt signaling
pathway that is critical for neurodevelopment, which is
differentially expressed in SZ brains,39 was signiﬁcantly
hypermethylated in major-psychosis females relative to
controls. The transcriptionally inducible nuclear-receptor
NR4A2, downregulated in both SZ and BD (see Figure 3A
and40), was found to be hypermethylated in SZ females.
FOSB, which encodes a protein controlling cell prolifera-
tion in the brain known to be expressed following chronic
antipsychotic treatment,41 was hypomethylated in ma-
jor-psychosis females relative to controls. Finally, the LIM
homeobox transcription factors LMX1B and LHX5, linked
to normal learning and motor functions,42 also showed
signiﬁcant methylation changes in female psychosis
samples, with LMX1B demonstrating putative hypome-
thylation and LHX5 demonstrating putative hypermethy-
lation.
Several other genes with links to major psychosis were
found to be epigenetically altered. Given that phospho-
lipid metabolism is disturbed in SZ,43 it is noteworthy
that the phospholipase gene PLA2G4B was hypermethy-
lated in SZ male, major-psychosis male, andmajor-psycho-
sis female samples. RAI1, hypermethylated in SZ female
samples, is located in an unstable genomic region encod-
ing a polymorphic polyglutamine tract associated with
SZ and response to antipsychotic medication.44 AUTS2,
hypermethylated in SZ male samples, spans a transloca-
tion breakpoint associated with mental retardation and
autism.45 Finally, a probe located ~90 kb upstreamof one of
our prenominated ‘‘psychosis-candidate genes,’’ DTNBP1,
was hypermethylated in affected females.
There is considerable clinical, epidemiological, genetic,
and neurochemical evidence to support a role for sex-
speciﬁc factors in the etiology of both SZ46 and BD.47 For
these reasons, our initial analyses considered males and fe-
males separately. It can be hypothesized that sex-speciﬁc
differences represent underlying differences in etiology
that may be mediated by epigenetic processes.48 For
example, although sex hormones cannot change DNA
sequence, it is known they can be potent modiﬁers of
epigenetic status and gene expression. There are several
reports of the female sex hormone estrogen, for example,
altering the chromatin-conﬁguration and DNA-methyla-
tion proﬁle of speciﬁc loci in the genome,49,50 potentially
controlling gene expression in a sex-speciﬁc manner. WeThewere also interested in the overlap between data from
male and female psychosis samples. Methylomic array
data from SZmales and SZ females were signiﬁcantly corre-
lated, signifying an overlap in the genomic regions epige-
netically altered in both sexes. Of particular interest was
evidence for FDR-signiﬁcant hypermethylation in both
male and female samples in the vicinity of two genes.
The ﬁrst is RPP21, which encodes a component of ribonu-
clease P, a protein complex that generates mature tRNA
molecules by cleaving their 50-ends19. The second is KEL,
encoding the Kell blood-group glycoprotein.20 Interest-
ingly, abnormal expression of Kell antigens is one cause
of McLeod Syndrome [MIM 314850], which is known to
manifest itself in symptoms of schizophrenia.51 Of note,
both RPP21 and KEL are also FDR-signiﬁcantly hyperme-
thylated in female BD samples. For BD, however, no signif-
icant overall correlation was found between males and
females, suggesting that sex-speciﬁc etiological factors
could play a stronger role in BD than SZ. Taken together,
these data reinforce the beneﬁts of performing epigenetic
studies separated by sex, but they also indicate that there
is signiﬁcant overlap between males and females for
DNA-methylation proﬁles associated with SZ.
No correlation was found between any demographic
variables or postmortem brain parameters and DNA meth-
ylation. Given the dynamic nature of the epigenome, how-
ever, and evidence linking drug exposure to DNA meth-
ylation, we also examined the epigenetic effect of
antipsychotic treatment. Methylation of a CpG island
located upstream of MEK1 was found to be strongly corre-
lated with antipsychotic use in SZ. This correlation was
particularly strong in male SZ samples, but it was also pres-
ent in female SZ samples. No correlation was seen in BD
samples. The link between MEK1 and antipsychotic expo-
sure in SZ is striking given the involvement of mitogen-
activated protein-kinase (MAPK) signaling pathways in
mediation of intraneuronal signaling and the observation
that clozapine, a widely used medication in the treatment
of SZ, selectively activates this pathway via an interaction
with MEK1.52
GO analysis allows the investigation of functionally
linked biological pathways in microarray datasets.53
Several interesting GO categories are highlighted by our
analysis, including several involved in various epigenetic
processes, transcription, and development. In addition,
we ﬁnd an association with genes involved in brain devel-
opment in both female BD and SZ samples and in response
to stress in male BD samples, consistent with the popular
diathesis-stress hypothesis of psychosis susceptibility. In
addition, given the postulated link between mitochondrial
dysfunction, oxidative stress, and psychosis,25 it is interest-
ing that a number of mitochondrial GO categories show
signiﬁcantly different distributions in affected individuals.
Our methylome results are in close agreement with a pa-
rallel microarray-based transcriptomics, proteomics, and
metabolomics study, also performed on brain tissue
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and proteins associated with mitochondrial function and
oxidative stress responses were the most altered group.25
Traditional etiological studies of complex disease, both
genetic and epigenetic, have tended to investigate discrete
regions of DNA in isolation. It is plausible, however, that
the epigenome, like many other biological systems,
comprises a complex network of interacting processes
and that DNA methylation in different genomic regions
is interdependent. Understanding the system-level
features of biological organization across the epigenome
is an important aspect of elucidating the epigenetic
changes associated with disease. In order to investigate
whether DNA methylation is coordinated across different
loci, we utilized a novel network-based approach to test
the modularity of our methylome data. In this way, a net-
work comprises distinct clusters of elements, termed
‘‘modules,’’ which are highly connected within themselves
but have fewer connections with the rest of the network.17
The study of interaction networks has proven fruitful in
many areas of biological research, highlighting distinct
modularity in metabolic networks,54 cellular networks,55
and protein-interaction networks.56 Although such an
approach has not been previously applied to the epige-
nome, recent evidence suggests the involvement of coordi-
nated epigenetic silencing across large genomic regions in
cancer.57
The goal of our network analysis was twofold: ﬁrst, to see
whether there is modularity in the methylome; second, if
such epigenetic modularity exists, to see whether there
are any differences between affected and unaffected
groups. For both brain and germline DNA, we found
evidence for signiﬁcant epigenetic modularity in both
groups analyzed. No modules were observed in a series of
simulated ‘‘random’’ datasets, suggesting that the modular
structure of the methylome is a real biological phenome-
non and that the epigenome can be split into distinct
groups of correlated loci, potentially corresponding to
distinct functional pathways and/or physical regions.
Although DNA methylation in both affected and unaf-
fected groups is clearly modular, the number of intercon-
nections between speciﬁc genomic regions is higher in
the affected group compared to the CTRL group, resulting
in more between-module interference, in both brain and
germline DNA. Given that modules within such biological
networks are likely to have speciﬁc functional tasks sepa-
rate to those of other modules,17 the lower degree of
DNA-methylation modularity observed in the major-
psychosis samples points to some degree of systemic epige-
netic dysfunction associated with major psychosis.
In addition to the microarray-based screening for epige-
netic changes, our second approach utilized in this study
focused on DNA methylation in the vicinity of genes
with a priori evidence for an etiological role in major
psychosis. These regions were proﬁled directly with bisul-
ﬁte modiﬁcation and pyrosequencing, with assays
designed to span CpG-rich promoter regions, along with
some exonic and intronic regions for several genes. Little708 The American Journal of Human Genetics 82, 696–711, Marchevidence was found to suggest that DNA methylation in
these genes is associated with either SZ or BD. Our analyses
included the promoter regions of both COMT and RELN
that have been previously shown to be epigenetically
altered in psychosis in previous studies.9,10,58 Unlike these
studies that report COMT hypomethylation and RELN
hypermethylation in SZ samples, we found no evidence
for DNA-methylation changes in these genes associated
with either SZ or BD. Our data are in agreement with a pre-
vious study on COMT reporting no association between
promoter methylation and major psychosis12 and a recent
study reporting very low levels of methylation across the
RELN region and no association with major psychosis.11
It should be noted that some of the methods used in previ-
ous studies of these genes, for example methylation-
speciﬁc PCR, can lead to biased assessment of methylated
cytosines and are not able to assess epigenetic changes in
a truly quantitative manner as is possible with the pyrose-
quencing methodology utilized in this study.
The observation of an association between genotype
at a nonsynonymous SNP (rs6265) in BDNF and DNA
methylation at surrounding CpG sites in DNA from fron-
tal-cortex brain tissue adds to the increasing evidence
that DNA sequences can inﬂuence epigenetic proﬁles
(e.g., 59,60). Although DNA alleles and haplotypes can be
subject to differential epigenetic modiﬁcation, it appears
that epigenetic status cannot be unequivocally deduced
from DNA-sequence data alone. The notion that epige-
netic changes might be associated with DNA-sequence
variation is relevant to the inconsistent genetic-association
studies in complex diseases and suggests that a comprehen-
sive epigenetic analysis of candidate SNPs and haplotypes
is warranted.
Our tandem use of two complementary approaches
allowed us to test both a priori hypotheses and identify
novel regions of the genome that may be epigenetically
dysfunctional in major psychosis. The unbiased microar-
ray approach was far more productive in identiﬁcation of
differentially methylated loci than was the focused candi-
date-gene approach; this has implications for the design of
future epigenetic studies of complex disease. Of note is the
observation that a high proportion of themicroarray-nom-
inated loci can be considered good functional and/or posi-
tional candidates. Given the relatively large number of
differences observed between affected and unaffected
individuals in our microarray screen and the laborious
nature of current bisulﬁte-based mapping approaches, it
was unfeasible to further investigate each nominated
gene at the level of speciﬁc CpG nucleotides in the course
of this study. Our analyses were stringently controlled for
multiple testing by use of the FDR statistic, but as with
all microarray-based experiments, it is possible that some
of the genes uncovered are false-positives; more in-depth
screening of speciﬁc gene regions will be needed to veri-
fy the speciﬁc DNA-methylation changes involved. In
general, the actual DNA-methylation differences observed
between major-psychosis and CTRL groups appear quite2008
subtle but consistent across affected individuals. This
pattern of ﬁndings reﬂects that seen for other etiological
approaches in major psychosis (e.g., gene-association stud-
ies, gene-expression studies, and brain-imaging studies)
and is as expected given the highly complex and heteroge-
neous nature of the phenotypes being studied.
It is plausible that differences in the cellular composition
of our brain-tissue samples can actually account for some
of the differences we observed. Conversely, however, we
cannot exclude the possibility that actual epigenetic
defects are more substantial than reported here but only
present in a speciﬁc cell type in the brain. This point is
highlighted by a recent study identifying epigenetic
changes occurring speciﬁcally in cortical-interneuron cells,
suggesting that different cell populations within a single
tissue type can have quite distinct epigenetic proﬁles.61
Of course, access to postmortem brain tissue from affected
individuals is difﬁcult, and at present it would probably
be very difﬁcult, logistically and ﬁnancially, to perform a
microarray-based study focused on various types of cell
populations. However, with the rapid technological
advances currently taking place, a future line of research
could be the search for cell-type-speciﬁc epimutations by
use of laser-capture microdissection technology, which en-
ables the isolation of single cells from whole tissue, thus
avoiding the confounding effects of cell-type variation.
Several strategies exist for enriching DNA prior to micro-
array hybridization, dependent upon DNA methylation
status. While each method has distinct advantages and
disadvantages, we utilized a method based on cleavage
with methylation-sensitive restriction enzymes.14 We
have previously veriﬁed this method, and shown it to be
both sensitive and repoducible.14,59 Because the majority
of CpG sites in the genome are methylated, it has been
shown that enrichment of the unmethylated DNA fraction
is more effective at detecting small DNA methylation
changes than alternative methods based on enrichment
of the methylated DNA fraction, such as methylated DNA
immunoprecipitation (MeDIP).62 Given the small DNA
methylation changes likely associated with complex dis-
eases such as psychosis, in part veriﬁed by the absolute
changes we detected in our study, such sensitivity is likely
to be a major advantage of our approach. One potential
limitation to all enrichment strategies is that they can be af-
fected by the presence of SNPs and copy number variation
(CNV). Until the full extent (and location) of CNV in the
genome is ascertained, it will be hard to fully address this
issue. Our bisulﬁte-mapping results suggest that neither
SNPs nor CNVs are systemically inﬂuencing ourmicroarray
data, but both should be taken into consideration when in-
vestigating further the epigenetic differences reported here.
Proving a direct causal link between epigenetic factors
and disease is not straightforward. It is possible that the
epigenetic differences observed actually result from
psychosis-induced changes in the brain. Tissues that are
not the disease site or directly affected by antipsychotic
medications, could thus actually be very useful in elucidat-The Aing epigenetic changes associated directly with major psy-
chosis. It has been proposed that germline epimutations
may be important in disease etiology,63 and potentially
transmitted between generations. A recent study from
our group reported considerable intra- and inter-individual
epigenetic variation in male germ cells.59 Our microarray
analysis of a BD germline DNA sample, however, did not
detect any FDR-signiﬁcant DNA methylation differences
associated with BD (Figure 3). The reason for discrepant
brain and the germline results could be numerous. For
example, epigenetic changes predisposing one to or caus-
ing major psychosis might be tissue-speciﬁc and restricted
to the main sites of disease manifestation (e.g., the brain).
In addition, previous studies of germline epimutations
have found that aberrantly methylated cytosines may be
present at very low frequencies (<1%),63 and such small
changes cannot be accurately detected with current micro-
array technology. Recent technological advances in DNA
methylation analysis, such as the deep-sequencing of bi-
sulﬁte-treated DNA, may make the detection of such min-
ute DNA methylation differences more easily detectable.
To conclude, consistent with the epigenetic theory of
major psychosis, a number of loci were found to be epige-
netically altered in the brain of SZ and BD patients relative
to unaffected controls. This study clearly demonstrates
that epigenomic studies can be done cost-effectively with
current technologies. Microarray technology is advancing
at a tremendous pace, and it will soon be economically
feasible to perform similar experiments on very high-
density tiling microarrays covering the entire genome.
Future studies can also be broadened to include other
epigenetic processes such as histone modiﬁcations and
small non-coding RNA molecules.
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